Raymond James & Associates Sells 39,358 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Raymond James & Associates trimmed its stake in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 4.7% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 794,957 shares of the medical research company's stock after selling 39,358 shares during the period. Raymond James & Associates owned about 0.44% of IQVIA worth $201,037,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently bought and sold shares of IQV. Norges Bank acquired a new position in IQVIA during the fourth quarter worth $383,705,000. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main boosted its stake in IQVIA by 339.6% during the fourth quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 2,067,195 shares of the medical research company's stock worth $478,308,000 after buying an additional 1,597,003 shares during the last quarter. AMF Tjanstepension AB acquired a new position in IQVIA during the third quarter worth $148,096,000. Morningstar Investment Services LLC boosted its stake in IQVIA by 96.9% during the fourth quarter. Morningstar Investment Services LLC now owns 1,231,916 shares of the medical research company's stock worth $286,704,000 after buying an additional 606,333 shares during the last quarter. Finally, Capital Research Global Investors boosted its stake in IQVIA by 42.2% during the fourth quarter. Capital Research Global Investors now owns 1,995,269 shares of the medical research company's stock worth $461,675,000 after buying an additional 592,372 shares during the last quarter. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on IQV shares. Barclays lifted their target price on IQVIA from $260.00 to $265.00 and gave the company an "overweight" rating in a research report on Thursday, February 15th. SVB Leerink started coverage on IQVIA in a research report on Monday, February 26th. They issued an "outperform" rating and a $290.00 target price on the stock. BTIG Research started coverage on IQVIA in a research report on Tuesday, February 13th. They issued a "buy" rating and a $285.00 target price on the stock. Evercore ISI lifted their target price on IQVIA from $255.00 to $265.00 and gave the company a "market outperform" rating in a research report on Thursday, February 15th. Finally, Truist Financial lifted their target price on IQVIA from $286.00 to $297.00 and gave the company a "buy" rating in a research report on Tuesday, February 27th. Three research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $256.80.

Insider Buying and Selling

In related news, insider Ari Bousbib sold 31,678 shares of the stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $250.53, for a total transaction of $7,936,289.34. Following the completion of the sale, the insider now owns 796,752 shares of the company's stock, valued at approximately $199,610,278.56. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other IQVIA news, insider Ari Bousbib sold 31,678 shares of the company's stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $250.53, for a total value of $7,936,289.34. Following the completion of the transaction, the insider now owns 796,752 shares in the company, valued at approximately $199,610,278.56. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Kevin C. Knightly sold 8,607 shares of the company's stock in a transaction that occurred on Wednesday, February 28th. The stock was sold at an average price of $250.17, for a total value of $2,153,213.19. Following the completion of the transaction, the insider now owns 5,251 shares of the company's stock, valued at approximately $1,313,642.67. The disclosure for this sale can be found here. In the last quarter, insiders sold 41,285 shares of company stock valued at $10,331,003. 1.60% of the stock is currently owned by corporate insiders.

IQVIA Trading Up 0.4 %

Shares of NYSE IQV traded up $0.90 on Friday, reaching $234.88. 697,640 shares of the company traded hands, compared to its average volume of 761,918. IQVIA Holdings Inc. has a fifty-two week low of $167.42 and a fifty-two week high of $261.73. The company has a 50 day moving average of $245.28 and a 200 day moving average of $223.17. The company has a current ratio of 0.86, a quick ratio of 0.86 and a debt-to-equity ratio of 2.12. The stock has a market capitalization of $42.63 billion, a PE ratio of 32.22, a P/E/G ratio of 2.26 and a beta of 1.50.

IQVIA (NYSE:IQV - Get Free Report) last posted its quarterly earnings data on Wednesday, February 14th. The medical research company reported $2.84 EPS for the quarter, beating analysts' consensus estimates of $2.82 by $0.02. The company had revenue of $3.87 billion during the quarter, compared to the consensus estimate of $3.80 billion. IQVIA had a net margin of 9.06% and a return on equity of 29.32%. The company's quarterly revenue was up 3.5% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.54 EPS. On average, equities research analysts forecast that IQVIA Holdings Inc. will post 10.12 earnings per share for the current fiscal year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.